EGFR and non-small cell lung carcinoma: Numerous clinical trials demonstrated significantly prolonged progression-free survival (PFS), overall survival (OS), and higher objective response rate (ORR) in EGFR-mutant NSCLC patients receiving first-/second-generation EGFR-TKIs than those receiving chemotherapy [7–9].